Keyphrases
Diabetes Medications
100%
Commercially Insured
100%
Dipeptidyl peptidase-4 (DPP-4)
100%
Antidiabetes Medication
100%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
75%
Sulfonylurea
50%
Health Care Costs
50%
Medical Costs
50%
A1 Receptor
50%
Receptor Agonist
50%
Medication Classes
50%
Thiazolidinediones
50%
Glucagon-like
50%
Non-pharmacy
50%
Type 2 Diabetes Mellitus (T2DM)
25%
High Cost
25%
Retrospective Cohort Study
25%
Glucagon-like peptide-1 (GLP-1)
25%
Medication Initiation
25%
Medication Cost
25%
Medication Therapy
25%
Main Drivers
25%
Patient-initiated
25%
Multivariable Regression Models
25%
Basal Insulin
25%
Class Change
25%
Medicine and Dentistry
Drug Therapy
100%
Diabetes
100%
Health Care Cost
100%
Dipeptidyl Peptidase-4 Inhibitor
36%
Sodium Glucose Cotransporter 2 Inhibitor
27%
Glucagon-Like Peptide-1 Agonist
18%
Thiazolidinedione
18%
Sulfonylurea
18%
Maturity Onset Diabetes of the Young
9%
Cohort Analysis
9%
Retrospective Cohort Study
9%
Glucagon Like Peptide 1
9%
Agricultural and Biological Sciences
Dipeptidyl Peptidase-4
100%
Cotransporter
75%
Agonist
50%
Health Care Cost
50%
Sulfonylurea
50%
Thiazolidinedione
50%
Glucagon-Like Peptide 1 Receptor
50%
Glucagon-Like Peptide-1
25%
Pharmacology, Toxicology and Pharmaceutical Science
Dipeptidyl Peptidase IV Inhibitor
100%
Sodium Glucose Cotransporter 2 Inhibitor
75%
Sulfonylurea
50%
Cohort Study
50%
Glucagon Like Peptide 1 Receptor Agonist
50%
Thiazolidinedione
50%
Glucagon-Like Peptide-1
25%
Non Insulin Dependent Diabetes Mellitus
25%
Nursing and Health Professions
Drug Therapy
100%
Dipeptidyl Peptidase IV Inhibitor
36%
Sodium Glucose Cotransporter 2 Inhibitor
27%
Health Care Cost
18%
Glucagon Like Peptide 1 Receptor Agonist
18%
Cohort Analysis
18%
Sulfonylurea
18%
Thiazolidinedione
18%
Non Insulin Dependent Diabetes Mellitus
9%
Glucagon Like Peptide 1
9%